Skip to main content

Cellumen Partners with Alzheimer's Foundation on Disease Modeling Systems

NEW YORK (GenomeWeb News) – Cellumen will partner with the Alzheimer’s Drug Discovery Foundation to develop a cellular model that could be used in Alzheimer’s treatments, the company said today.
 
Pittsburgh-based Cellumen plans to use its Cellular Systems Biology technology to develop a panel of assays and biosensors of protein interactions in order to find targets and pathways involved in the disease. This technology could allow researchers to conduct more clinically relevant drug screening, the company believes.
 
“We have the opportunity to revolutionize the treatment of this complex disease by providing pharmaceutical companies with the necessary tools to identify novel chemical modulators of the AD systems biology,” Cellumen CEO Lansing Taylor said in a statement.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.